TS-142
Phase 3Small molecule
TS-142 is one of 78 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 3.
2
Indications
14
Total Trials
0
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
153 competitors in Insomnia
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Hetlioz
VVanda Pharmaceuticals
Phase 3
Gaboxadol
LundbeckPhase 3
Eplivanserin
SanofiPhase 3
Volinanserin
SanofiPhase 3
Prosom
AAbbott
Phase 3
Org 50081
Merck & Co.Phase 3
Nitrazepam
AstellasPhase 3
MK0928, Gaboxadol
LundbeckPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Insomnia4 trials
Adult Subject3 trials
Driving1 trial
Obstructive Sleep Apnea1 trial
4 more indications
Elderly1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TS-142. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTaisho Pharmaceutical Co., Ltd.